FR2215946A1 - Inactivating viruses for vaccine prodn. - by freez-drying in presence of protein stabilizer then heating - Google Patents

Inactivating viruses for vaccine prodn. - by freez-drying in presence of protein stabilizer then heating

Info

Publication number
FR2215946A1
FR2215946A1 FR7403925A FR7403925A FR2215946A1 FR 2215946 A1 FR2215946 A1 FR 2215946A1 FR 7403925 A FR7403925 A FR 7403925A FR 7403925 A FR7403925 A FR 7403925A FR 2215946 A1 FR2215946 A1 FR 2215946A1
Authority
FR
France
Prior art keywords
virus
esp
strain
mins
freez
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR7403925A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of FR2215946A1 publication Critical patent/FR2215946A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18661—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18861—Methods of inactivation or attenuation

Abstract

The freeze-dried virus-stabiliser prod is heated at 50-150 degress C esp. 90-125 degrees C for 5-35 mins, pspec. 100 degrees C for 20, mins. Stabilisers are suitably heat- or acid-degraded gelatine, opt. contg. sorbitol or a compsn contg albumin, sugar phosphate and glutamine and are used at 1 mu g-30mg per haemagglutination unit. Viruses are esp. adeno- or myxoviruses esp. Sendai virus strain M34996, measles virus Edmonton strain, influenza strain WRL 55 or infectious canine hepatitis virus. The process leaves the nanogranular layer of the myxovirus intact and vaccines have better storage stability than those produced by chemical inactivation of the virus.
FR7403925A 1973-02-07 1974-02-06 Inactivating viruses for vaccine prodn. - by freez-drying in presence of protein stabilizer then heating Withdrawn FR2215946A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB593673 1973-02-07

Publications (1)

Publication Number Publication Date
FR2215946A1 true FR2215946A1 (en) 1974-08-30

Family

ID=9805407

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7403925A Withdrawn FR2215946A1 (en) 1973-02-07 1974-02-06 Inactivating viruses for vaccine prodn. - by freez-drying in presence of protein stabilizer then heating

Country Status (8)

Country Link
JP (1) JPS49109520A (en)
AU (1) AU6525274A (en)
BE (1) BE810697A (en)
DE (1) DE2405675A1 (en)
ES (1) ES422966A1 (en)
FR (1) FR2215946A1 (en)
IL (1) IL44143A0 (en)
NL (1) NL7401610A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028563A1 (en) * 1979-10-29 1981-05-13 Merck & Co. Inc. Stabilizer for liquid vaccines and liquid vaccine containing said stabilizer
EP0030199A2 (en) * 1979-12-03 1981-06-10 Merck & Co. Inc. Lyophilization process for live viral compositions
FR2505657A1 (en) * 1981-05-13 1982-11-19 Pasteur Institut IMPROVEMENTS IN LIVE STABILIZING AGENTS FOR THE PREPARATION OF VACCINES, AND STABILIZED VACCINES CONTAINING SAID STABILIZING AGENTS
FR2532548A1 (en) * 1982-09-03 1984-03-09 Pasteur Institut New method for producing vaccines possessing a high titre of virus, and highly purified vaccines having a high titre of virus thereby obtained

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL191729C (en) * 1978-04-12 1996-05-03 Merck & Co Inc Stabilized vaccine.
JPS57114527A (en) * 1979-10-29 1982-07-16 Merck & Co Inc Vaccine stabilizer
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
JPS577423A (en) * 1980-06-13 1982-01-14 Takeda Chem Ind Ltd Frozen or freeze-dried live measles vaccine
US4695454A (en) * 1985-04-01 1987-09-22 New York Blood Center, Inc. Process for preparing hepatitis B surface antigen containing particles in novel forms which are highly immunogenic
JPH0759759B2 (en) * 1988-10-29 1995-06-28 株式会社日立製作所 Method and apparatus for descaling annealed stainless steel strip
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028563A1 (en) * 1979-10-29 1981-05-13 Merck & Co. Inc. Stabilizer for liquid vaccines and liquid vaccine containing said stabilizer
EP0030199A2 (en) * 1979-12-03 1981-06-10 Merck & Co. Inc. Lyophilization process for live viral compositions
EP0030199A3 (en) * 1979-12-03 1982-06-09 Merck & Co. Inc. Lyophilization process for live viral compositions
FR2505657A1 (en) * 1981-05-13 1982-11-19 Pasteur Institut IMPROVEMENTS IN LIVE STABILIZING AGENTS FOR THE PREPARATION OF VACCINES, AND STABILIZED VACCINES CONTAINING SAID STABILIZING AGENTS
EP0065905A1 (en) * 1981-05-13 1982-12-01 Institut Pasteur Stabilizing agents for live viruses for the preparation of vaccines, and stabilized vaccines containing these stabilizing agents
US4500512A (en) * 1981-05-13 1985-02-19 Institut Pasteur Stabilizing agents for live viruses for preparing vaccines, and stabilized vaccines containing said stabilizing agents
FR2532548A1 (en) * 1982-09-03 1984-03-09 Pasteur Institut New method for producing vaccines possessing a high titre of virus, and highly purified vaccines having a high titre of virus thereby obtained

Also Published As

Publication number Publication date
AU6525274A (en) 1975-08-07
BE810697A (en) 1974-08-06
NL7401610A (en) 1974-08-09
JPS49109520A (en) 1974-10-18
IL44143A0 (en) 1974-05-16
ES422966A1 (en) 1976-06-01
DE2405675A1 (en) 1974-08-15

Similar Documents

Publication Publication Date Title
FR2215946A1 (en) Inactivating viruses for vaccine prodn. - by freez-drying in presence of protein stabilizer then heating
Choppin et al. Reproduction of paramyxoviruses
JPS6259088B2 (en)
US20040053316A1 (en) Methods and compositions for the selective modification of nucleic acids
JPS6230752B2 (en)
Bratt et al. Genetics and paragenetic phenomena of paramyxoviruses
US4064232A (en) Process for isolating the immunogenic components of influenza viruses
US4140762A (en) Influenza sub-unit vaccine
IE40180B1 (en) Influenza virus vaccines and preparation thereof
ES355121A1 (en) Procedure for the preparation of an antigen-free vaccine. (Machine-translation by Google Translate, not legally binding)
CA1049406A (en) Isolation of hemagglutinin and neuraminidase from influenza virus
De Jong et al. Inactivation of encephalomyocarditis virus in aerosols: fate of virus protein and ribonucleic acid
ES432385A1 (en) Influenza vaccines
US3259546A (en) Treatment of viruses
Polley Factors influencing inactivation of infectivity and hemagglutinin of influenza virus by gamma radiation
ATE1044T1 (en) VACCINE AGAINST INFECTIOUS PERITONITIS OF THE FELIDS AND PROCESS FOR ITS PRODUCTION.
FR2270892A1 (en) Vaccines from attenuated viruses - which have been serially incubated with yeast cells, especially Saccharomyces cerevisiae
Mekler et al. Sendai virus RNA as messenger RNA determining the synthesis of early virus specific proteins
Nakamura A comparison of the yields of infectious ribonucleic acid from heated and ultraviolet irradiated mouse encephalomyelitis virus (GDVII strain)
RU1822791C (en) Method of preparing of inactivated influenza vaccine
Hosai et al. Studies on live attenuated mumps virus vaccine. 1. Attenuation of mumps virus by serial passage in the chorioallantoic cavity of developing chick embryos and field trials by the inhalation method
FR2261779A1 (en) Anti-rabies vaccine - obtd. from rabies virus grown on foetal calf kidney cells in a synthetic serum-free medium
Umekawa et al. Sensitivity of tobacco mosaic virus to ultraviolet irradiation
CA2006078A1 (en) Method for disrupting virus particles
Glück et al. New aspects concerning the immunogenicity of rabies vaccines produced in animal brains (duck embryo)

Legal Events

Date Code Title Description
ST Notification of lapse